GlassScriptPhysician profile
Shehab Saddy
NPI 1902986466
$8,126.46
in general payments reported to CMS, 2019-2025
32 companies · $450 in 2025
The $450 reported for 2025 was more than what 77% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $712 · 2021: $1,538 · 2022: $1,486 · 2023: $1,545 · 2024: $790 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,308.80 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $1,062.84 | 2021-2024 | Vraylar |
| Bioventus LLC | $848.10 | 2019 | |
| Novo Nordisk INC | $579.60 | 2020-2024 | Wegovy |
| Abbott Laboratories | $486.75 | 2022-2023 | Freestyle Libre 3 |
| Allergan, INC. | $447.40 | 2019-2021 | |
| Amgen INC. | $295.23 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.68 | 2020-2022 | |
| Astellas Pharma US INC | $249.93 | 2019 | |
| Kyowa Kirin, INC. | $246.85 | 2021-2023 | Nourianz |
| Dexcom, INC. | $233.23 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $232.10 | 2022-2025 | Rexulti |
| Edwards Lifesciences Corporation | $221.35 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Amneal Pharmaceuticals LLC | $203.12 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $164.70 | 2025 | Venclose Maven Catheter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $161.39 | 2020-2024 | Tymlos |
| Biogen, INC. | $142.20 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $140.55 | 2020-2023 | Breztri |
| Merz Pharmaceuticals, LLC | $137.22 | 2022-2023 | Xeomin |
| Lundbeck LLC | $86.78 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $84.99 | 2025 | General - Pain Management |
| Sanofi Pasteur INC. | $77.10 | 2019 | |
| Pfizer INC. | $73.58 | 2021 | |
| Axsome Therapeutics, INC. | $70.69 | 2024-2025 | Auvelity |
| Galderma Laboratories, L.P. | $63.35 | 2022 | |
| Merz North America, INC. | $54.74 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.96 | 2024 | Rexulti |
| Lilly USA, LLC | $33.00 | 2022 | |
| Exact Sciences Corporation | $30.53 | 2025 | |
| Eisai INC. | $26.15 | 2024 | |
| Avion Pharmaceuticals | $25.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehab Saddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.